Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery

Journal of Experimental & Clinical Cancer Research

Nicolae Ghinea⁴  Martine Antoine²  Xavier Sastre-Garau³  Christophe Pichon⁴  Blaise Robin⁴  François-Clément Bidard¹  Mohammad-Ahsan Siraj⁴  François Planeix⁴ 

[1] Curie Hospital, Oncology Department, 26 rue d’Ulm, Paris, France;Tenon Hospital, Pathology Department, 4 rue de la Chine, Paris, France;Curie Hospital, Pathology Department, 26 rue d’Ulm, Paris, France;INSERM “Tumoral Angiogenesis” Laboratory, Curie Institute, Research Center, Translational Research Department, 26 rue d’Ulm, Paris, France

关键词: Vascular remodeling;    Triple negative breast cancer;    Progesterone receptor;    Podoplanin;    Lymphangiogenesis;    HER2;    FSHR;    Estrogen receptor;    CD34;    Breast cancer subtype;    Angiogenesis;   

Others  :  1133390
DOI  :  10.1186/s13046-015-0128-7

 received in 2014-12-22, accepted in 2015-01-20,  发布年份 2015

【 摘 要 】

Background

Follicle-stimulating hormone receptor (FSHR) is expressed on the endothelial surface of blood vessels associated with solid tumor periphery, where angiogenesis is known to occur. The correlation between FSHR expression and formation of new peritumoral vessels has not been previously investigated.

Methods

We used immunohistochemical techniques involving specific antibodies to detect FSHR and the endothelial markers (CD34, VEGFR2, and D2-40) in tissue samples from 83 patients with lymph node-negative, invasive breast cancer representing four main clinical treatment groups: HR+/HER2-, HR+/HER2+, HR-/HER2+ and triple-negative.

Results

The FSHR+ vessels were exclusively located at breast cancer periphery, in a layer that extended 2 mm into and 5 mm outside of the tumor. The percentage of blood vessels expressing FSHR reached a maximum of 100% at the demarcation line between the tumor and the normal tissue. Common among FSHR+ vessels, regardless of breast cancer type, were the high densities of arterioles and venules (6.4 ± 1.4 and 13.9 ± 2.1 vessels/mm², respectively). These values were 3-fold higher that those noticed for CD34+ arterioles and venules associated with normal breast tissue located at a distance greater than 10 mm outside the tumors. The average density of FSHR+ and CD34+ blood vessels as well as of D2-40+ lymphatic vessels did not differ significantly among breast cancer subgroups. FSHR+ vessels did not express VEGFR2. The endothelial FSHR expression correlated significantly with the peritumoral CD34+ vessels’ density (p < 0.001) and tumor size (p = 0.01).

Conclusion

Endothelial FSHR expression in breast cancer is associated with vascular remodeling at tumor periphery.

【 授权许可】

   
2015 Planeix et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-403.
• [2]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-22.
• [3]Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al.: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-9.
• [4]Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL: Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987, 235:177-82.
• [5]Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, et al.: Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011, 29:3885-91.
• [6]Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-91.
• [7]Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-8.
• [8]Abramson VA, Lehman BD, Ballinger TJ, Pietenpol JA: Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 2014.
• [9]Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.: Molecular classification of breast cancer based on gene expression profiles can be also used to characterize the type of tumor in regards of the actual convention. Nature 2000, 406:747-52.
• [10]Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-7.
• [11]Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23.
• [12]Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012, 12:323-34.
• [13]Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England J Med 2012, 366:883-92.
• [14]Swanton C: Intratumor heterogeneity: Evolution through space and time. Cancer Res 2012, 72:4875-82.
• [15]Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990, 82:4-6.
• [16]Thorpe PE: Vascular Targeting Agents as Cancer Therapeutics. Clin Cancer Res 2004, 10:415-27.
• [17]Neri D, Bicknell R: Tumor vascular targeting. Nature Rev Cancer 2005, 5:436-46.
• [18]Claesson-Welsh L: Blood vessels as targets in tumor therapy. Ups J Med Sci. 2012, 117:178-86.
• [19]Siemann DW, Chaplin DJ, Horsman MR: Vascular targeting therapies for treatment of malignant disease. Cancer 2004, 100:2491-9.
• [20]Nagy JA, Dvorak HF: Heterogeneity of tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 2012, 29:657-62.
• [21]Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, et al.: Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010, 363:1621-30.
• [22]Ghinea N: A novel role for FSH receptor as a tumor endothelial marker. Acta Endocrinologica (Buc). 2010, 6:507-12.
• [23]Siraj A, Desestret V, Antoine M, Fromont G, Huerre M, Sanson M, et al.: Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC Cancer 2013, 13:246. doi: 10.1186/1471-2407-13-246 BioMed Central Full Text
• [24]Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, et al.: Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993, 53:4161-3.
• [25]Vannier B, Loosfelt H, Meduri G, Pichon C, Milgrom E: Anti-human FSH receptor monoclonal antibodies: Immunochemical and immunocytochemical characterization of the receptor. Biochemistry 1996, 35:1358-66.
• [26]Simionescu N, Simionescu M: The cardiovascular system. In “Cell and tissue biology. A textbook of histology”, Weiss L, editor. Sixth edition, Urban & Schwarzenberg , Baltimore, Munchen 1988, Chapter 10: 353–400.
• [27]Bocci G, Danesi R: benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M. Inhibitory effect of suranim in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999, 43:205-12.
• [28]Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997, 57:765-72.
• [29]Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al.: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-80.
• [30]Pries AS, Höpfner M, Le Noble F, Dewhirst MW, Secomb TW: The shunt problem: control of functional shunting in normal and tumor vasculature. Nature Rev Cancer 2010, 10:587-92.
• [31]Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347:1227-32.
• [32]Keereweer S, Van Driel PB, Robinson DJ, Lowik CW: Shifting focus in optical image-guided cancer therapy. Mol Imaging Biol 2014, 16:1-9.
• [33]Fakhrejahani E, Toi M: Antiangiogenesis therapy for breast cancer: An update and perspectives from clinical Trials. Jpn J Clin Oncol 2014, 44:197-207.
• [34]Ghiringhelli F, Isambert N, Ladoire S: Degarelix as a new antiangiogenic agent for metastatic colon cancer? World J Gastroenterol 2013, 19:769-72.